Yersiniosis belongs to the common foodborne diseases around the world, and frequently manifests as diarrhea that can be treated with probiotics. Colicin FY is an antibacterial agent produced by bacteria and it is capable of specific growth inhibition of Yersinia enterocolitica, the causative agent of gastrointestinal yersiniosis. In this study, recombinant E. coli producing colicin FY were constructed, using both known probiotic strains EcH22 and EcColinfant, and the newly isolated murine strains Ec1127 and Ec1145. All E. coli strains producing colicin FY inhibited growth of pathogenic Y. enterocolitica during co-cultivation in vitro. In dysbiotic mice treated with streptomycin, E. coli strains producing colicin FY inhibited progression of Y. enterocolitica infections. This growth inhibition was not observed in mice with normal gut microflora, likely due to insufficient colonization capacity of E. coli strains and/or due to spatial differences in intestinal niches. Isogenic Y. enterocolitica producing colicin FY was constructed and shown to inhibit pathogenic Y. enterocolitica in mice with normal microflora. Evidence of in vivo antimicrobial activity of colicin FY may have utility in the treatment of Y. enterocolitica infections.

Department of Biology Faculty of Medicine Masaryk University Brno Czech Republic

Research Centre for Toxic Compounds in the Environment Faculty of Science Masaryk University Brno Czech Republic

Veterinary Research Institute Brno Czech Republic

Zobrazit více v PubMed

EFSA (European Food Safety Authority) and ECDC (European Centre for Disease Prevention and Control) The European Union summary report on trends and sources of zoonoses, zoonotic agents and food‐borne outbreaks in 2016. EFSA J. 15, 10.2903/j.efsa.2017.5077 (2017). PubMed PMC

Scallan E, et al. Foodborne illness acquired in the United States–major pathogens. Emerg. Infect. Dis. 2011;17:7–15. doi: 10.3201/eid1701.P11101. PubMed DOI PMC

Ong KL, et al. Changing epidemiology of Yersinia enterocolitica infections: markedly decreased rates in young black children, Foodborne Diseases Active Surveillance Network (Food Net), 1996–2009. Clin. Infect. Dis. 2012;54:S385–S390. doi: 10.1093/cid/cis053. PubMed DOI PMC

Bottone EJ. Yersinia enterocolitica: the charisma continues. Clin. Microbiol. Rev. 1997;10:257–276. PubMed PMC

Ray SM, et al. Population‐based surveillance for Yersinia enterocolitica infections in FoodNet Sites, 1996–1999: higher risk of disease in infants and minority populations. Clin. Infect. Dis. 2004;38:S181–S189. doi: 10.1086/381585. PubMed DOI

Duan R, et al. Prevalence of Yersinia enterocolitica Bioserotype 3/O:3 among children with diarrhea, China, 2010–2015. Emerg. Infect. Dis. 2017;23:1502–1509. doi: 10.3201/eid2309.160827. PubMed DOI PMC

Marimon JM, et al. Thirty years of human infections caused by Yersinia enterocolitica in northern Spain: 1985–2014. Epidemiol. Infect. 2017;145:2197–2203. doi: 10.1017/S095026881700108X. PubMed DOI PMC

Saebo A, Vik E, Lange OJ, Matuszkiewicz L. Inflammatory bowel disease associated with Yersinia enterocolitica O:3 infection. Eur. J. Intern. Med. 2005;16:176–182. doi: 10.1016/j.ejim.2004.11.008. PubMed DOI

Bottone EJ. Yersinia enterocolitica: overview and epidemiologic correlates. Microbes Infect. 1999;1:323–333. doi: 10.1016/S1286-4579(99)80028-8. PubMed DOI

Abdel-Haq NM, Asmar BI, Abuhammour WM, Brown WJ. Yersinia enterocolitica infection in children. Pediatr. Infect. Dis. J. 2000;19:954–958. doi: 10.1097/00006454-200010000-00002. PubMed DOI

Pineiro M, Stanton C. Probiotic bacteria: legislative framework–requirements to evidence basis. J. Nutr. 2007;137:850S–3S. doi: 10.1093/jn/137.3.850S. PubMed DOI

Wassenaar TM. Insights from 100 years of research with probiotic E. coli. Eur. J. Microbiol. Immunol. 2016;6:147–161. doi: 10.1556/1886.2016.00029. PubMed DOI PMC

Dobson A, Cotter PD, Ross RP, Hill C. Bacteriocin production: a probiotic trait? Appl. Environ. Microbiol. 2012;78:1–6. doi: 10.1128/AEM.05576-11. PubMed DOI PMC

Gillor O, Kirkup BC, Riley MA. Colicins and microcins: the next generation antimicrobials. Adv. Appl. Microbiol. 2004;54:129–146. doi: 10.1016/S0065-2164(04)54005-4. PubMed DOI

Diez-Gonzalez F. Applications of bacteriocins in livestock. Curr. Issues Intest. Microbiol. 2007;8:15–23. PubMed

Micenková L, Bosák J, Vrba M, Ševčíková A, Šmajs D. Human extraintestinal pathogenic Escherichia coli strains differ in prevalence of virulence factors, phylogroups, and bacteriocin determinants. BMC Microbiol. 2016;16:218. doi: 10.1186/s12866-016-0835-z. PubMed DOI PMC

Micenková L, et al. Bacteriocin-encoding genes and ExPEC virulence determinants are associated in human fecal Escherichia coli strains. BMC Microbiol. 2014;14:109. doi: 10.1186/1471-2180-14-109. PubMed DOI PMC

Šmarda J, Šmajs D. Colicins–exocellular lethal proteins of Escherichia coli. Folia Microbiol. (Praha). 1998;43:563–582. doi: 10.1007/BF02816372. PubMed DOI

Cascales E, et al. Colicin biology. Microbiol. Mol. Biol. Rev. 2007;71:158–229. doi: 10.1128/MMBR.00036-06. PubMed DOI PMC

Bosák J, Laiblová P, Šmarda J, Dědičová D, Šmajs D. Novel colicin FY of Yersinia frederiksenii inhibits pathogenic Yersinia strains via YiuR-mediated reception, TonB import, and cell membrane pore formation. J. Bacteriol. 2012;194:1950–1959. doi: 10.1128/JB.05885-11. PubMed DOI PMC

Bosák J, et al. Unique activity spectrum of colicin FY: All 110 characterized Yersinia enterocolitica isolates were colicin FY susceptible. Plos One. 2013;8:e81829. doi: 10.1371/journal.pone.0081829. PubMed DOI PMC

Bosák J, Micenková L, Doležalová M, Šmajs D. Colicins U and Y inhibit growth of Escherichia coli strains via recognition of conserved OmpA extracellular loop 1. Int. J. Med. Microbiol. 2016;306:486–494. doi: 10.1016/j.ijmm.2016.07.002. PubMed DOI

Patton BS, Dickson JS, Lonergan SM, Cutler SA, Stahl CH. Inhibitory activity of colicin E1 against Listeria monocytogenes. J. Food Prot. 2007;70:1256–1262. doi: 10.4315/0362-028X-70.5.1256. PubMed DOI

Šmajs D, Pilsl H, Braun V. Colicin U, a novel colicin produced by Shigella boydii. J. Bacteriol. 1997;179:4919–4928. doi: 10.1128/jb.179.15.4919-4928.1997. PubMed DOI PMC

Šmajs D, Weinstock GM. The iron- and temperature-regulated cjrBC genes of Shigella and enteroinvasive Escherichia coli strains code for colicin Js uptake. J. Bacteriol. 2001;183:3958–3966. doi: 10.1128/JB.183.13.3958-3966.2001. PubMed DOI PMC

Spees AM, et al. Streptomycin-induced inflammation enhances Escherichia coli gut colonization through nitrate respiration. MBio. 2013;4:e00430–13. doi: 10.1128/mBio.00430-13. PubMed DOI PMC

Sassone-Corsi, M. et al. Microcins mediate competition among Enterobacteriaceae in the inflamed gut. Nat. Publ. Gr. 540, 10.1038/nature20557 (2016). PubMed PMC

Cursino L, et al. Exoproducts of the Escherichia coli strain H22 inhibiting some enteric pathogens both in vitro and in vivo. J. Appl. Microbiol. 2006;100:821–829. doi: 10.1111/j.1365-2672.2006.02834.x. PubMed DOI

Hu PC, Yang GC, Brubaker RR. Specificity, induction, and absorption of pesticin. J. Bacteriol. 1972;112:212–219. PubMed PMC

Strauch E, et al. Characterization of enterocoliticin, a phage tail-like bacteriocin, and its effect on pathogenic Yersinia enterocolitica strains. Appl. Environ. Microbiol. 2001;67:5634–5642. doi: 10.1128/AEM.67.12.5634-5642.2001. PubMed DOI PMC

Damasko C, et al. Studies of the efficacy of enterocoliticin, a phage-tail like bacteriocin, as antimicrobial agent against Yersinia enterocolitica serotype O3 in a cell culture system and in mice. J. Vet. Med. Ser. B. 2005;52:171–179. doi: 10.1111/j.1439-0450.2005.00841.x. PubMed DOI

Heesemann J, Gaede K, Autenrieth IB. Experimental Yersinia enterocolitica infection in rodents: a model for human yersiniosis. APMIS. 1993;101:417–429. doi: 10.1111/j.1699-0463.1993.tb00130.x. PubMed DOI

Schippers A, et al. Susceptibility of four inbred mouse strains to a low-pathogenic isolate of Yersinia enterocolitica. Mamm. Genome. 2008;19:279–291. doi: 10.1007/s00335-008-9105-1. PubMed DOI

Kerr B, Riley MA, Feldman MW, Bohannan BJM. Local dispersal promotes biodiversity in a real-life game of rock–paper–scissors. Nature. 2002;418:171–174. doi: 10.1038/nature00823. PubMed DOI

Kirkup BC, Riley MA. Antibiotic-mediated antagonism leads to a bacterial game of rock–paper–scissors in vivo. Nature. 2004;428:412–414. doi: 10.1038/nature02429. PubMed DOI

Riley MA, Wertz JE. Bacteriocins: evolution, ecology, and application. Annu. Rev. Microbiol. 2002;56:117–137. doi: 10.1146/annurev.micro.56.012302.161024. PubMed DOI

Hegarty JW, Guinane CM, Ross RP, Hill C, Cotter PD. Bacteriocin production: a relatively unharnessed probiotic trait? F1000Research. 2016;5:2587. doi: 10.12688/f1000research.9615.1. PubMed DOI PMC

Sassone-Corsi M, Raffatellu M. No vacancy: how beneficial microbes cooperate with immunity to provide colonization resistance to pathogens. J. Immunol. 2015;194:4081–4087. doi: 10.4049/jimmunol.1403169. PubMed DOI PMC

Ikari NS, Kenton DM, Young VM. Interaction in the germfree mouse intestine of colicinogenic and colicin-sensitive microorganisms. Proc. Soc. Exp. Biol. Med. 1969;130:1280–1284. doi: 10.3181/00379727-130-33773. PubMed DOI

Gillor O, Giladi I, Riley MA. Persistence of colicinogenic Escherichia coli in the mouse gastrointestinal tract. BMC Microbiol. 2009;9:165. doi: 10.1186/1471-2180-9-165. PubMed DOI PMC

Kelstrup J, Gibbons RJ. Inactivation of bacteriocins in the intestinal canal and oral cavity. J. Bacteriol. 1969;99:888–890. PubMed PMC

Braun V, Frenz J, Hantke K, Schaller K. Penetration of colicin M into cells of Escherichia coli. J. Bacteriol. 1980;142:162–168. PubMed PMC

Deriu E, et al. Probiotic bacteria reduce Salmonella Typhimurium intestinal colonization by competing for iron. Cell Host Microbe. 2013;14:26–37. doi: 10.1016/j.chom.2013.06.007. PubMed DOI PMC

Schumann S, Alpert C, Engst W, Loh G, Blaut M. Dextran sodium sulfate-induced inflammation alters the expression of proteins by intestinal Escherichia coli strains in a gnotobiotic mouse model. Appl. Environ. Microbiol. 2012;78:1513–1522. doi: 10.1128/AEM.07340-11. PubMed DOI PMC

Stecher B. The roles of inflammation, nutrient availability and the commensal microbiota in enteric pathogen infection. Metabolism and Bacterial Pathogenesis. 2015;3:297–320. doi: 10.1128/microbiolspec.MBP-0008-2014. PubMed DOI

Gillor O, Vriezen JAC, Riley MA. The role of SOS boxes in enteric bacteriocin regulation. Microbiology. 2008;154:1783–1792. doi: 10.1099/mic.0.2007/016139-0. PubMed DOI PMC

Nedialkova LP, et al. Inflammation fuels colicin Ib-dependent competition of Salmonella serovar Typhimurium and E. coli in enterobacterial blooms. Plos Pathog. 2014;10:e1003844. doi: 10.1371/journal.ppat.1003844. PubMed DOI PMC

Barthel M, et al. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect. Immun. 2003;71:2839–2858. doi: 10.1128/IAI.71.5.2839-2858.2003. PubMed DOI PMC

Lawley TD, Walker AW. Intestinal colonization resistance. Immunology. 2013;138:1–11. doi: 10.1111/j.1365-2567.2012.03616.x. PubMed DOI PMC

Corr SC, et al. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. USA. 2007;104:7617–7621. doi: 10.1073/pnas.0700440104. PubMed DOI PMC

Frick JS, et al. Lactobacillus fermentum attenuates the proinflammatory effect of Yersinia enterocolitica on human epithelial cells. Inflamm. Bowel Dis. 2007;13:83–90. doi: 10.1002/ibd.20009. PubMed DOI

Frick JS, et al. Identification of commensal bacterial strains that modulate Yersinia enterocolitica and dextran sodium sulfate-induced inflammatory responses: implications for the development of probiotics. Infect. Immun. 2007;75:3490–3497. doi: 10.1128/IAI.00119-07. PubMed DOI PMC

De Montijo-Prieto S, et al. A Lactobacillus plantarum strain isolated from kefir protects against intestinal infection with Yersinia enterocolitica O9 and modulates immunity in mice. Res. Microbiol. 2015;166:626–632. doi: 10.1016/j.resmic.2015.07.010. PubMed DOI

Millette M, et al. Capacity of human nisin- and pediocin-producing lactic acid bacteria to reduce intestinal colonization by vancomycin-resistant enterococci. Appl. Environ. Microbiol. 2008;74:1997–2003. doi: 10.1128/AEM.02150-07. PubMed DOI PMC

Walsh MC, et al. Predominance of a bacteriocin-producing Lactobacillus salivarius component of a five-strain probiotic in the porcine ileum and effects on host immune phenotype. FEMS Microbiol. Ecol. 2008;64:317–327. doi: 10.1111/j.1574-6941.2008.00454.x. PubMed DOI

Lopez FE, Vincent PA, Zenoff AM, Salomón RA, Farías RN. Efficacy of microcin J25 in biomatrices and in a mouse model of Salmonella infection. J. Antimicrob. Chemother. 2007;59:676–680. doi: 10.1093/jac/dkm009. PubMed DOI

Stern NJ, et al. Bacteriocins reduce Campylobacter jejuni colonization while bacteria producing bacteriocins are ineffective. Microb. Ecol. Health Dis. 2008;20:74–79. doi: 10.1080/08910600802030196. DOI

Batzilla J, Antonenka U, Höper D, Heesemann J, Rakin A. Yersinia enterocolitica palearctica serobiotype O:3/4–a successful group of emerging zoonotic pathogens. BMC Genomics. 2011;12:348. doi: 10.1186/1471-2164-12-348. PubMed DOI PMC

Micenková L, et al. Human Escherichia coli isolates from hemocultures: Septicemia linked to urogenital tract infections is caused by isolates harboring more virulence genes than bacteraemia linked to other conditions. Int. J. Med. Microbiol. 2017;307:182–189. doi: 10.1016/j.ijmm.2017.02.003. PubMed DOI

Rossignol M, Basset A, Espéli O, Boccard F. NKBOR, a mini-Tn10-based transposon for random insertion in the chromosome of Gram-negative bacteria and the rapid recovery of sequences flanking the insertion sites in Escherichia coli. Res. Microbiol. 2001;152:481–485. doi: 10.1016/S0923-2508(01)01221-9. PubMed DOI

Thomson NR, et al. The complete genome sequence and comparative genome analysis of the high pathogenicity Yersinia enterocolitica strain 8081. Plos Genet. 2006;2:e206. doi: 10.1371/journal.pgen.0020206. PubMed DOI PMC